These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38911030)

  • 41. Putative protective role of lutein and zeaxanthin in diabetic retinopathy.
    Neelam K; Goenadi CJ; Lun K; Yip CC; Au Eong KG
    Br J Ophthalmol; 2017 May; 101(5):551-558. PubMed ID: 28232380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melatonin in the eye: implications for glaucoma.
    Lundmark PO; Pandi-Perumal SR; Srinivasan V; Cardinali DP; Rosenstein RE
    Exp Eye Res; 2007 Jun; 84(6):1021-30. PubMed ID: 17174303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.
    Scott IU; Jackson GR; Quillen DA; Larsen M; Klein R; Liao J; Holfort S; Munch IC; Gardner TW
    JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
    Behar-Cohen F; Dernigoghossian M; Andrieu-Soler C; Levy R; Cohen R; Zhao M
    Drug Discov Today; 2019 Aug; 24(8):1436-1439. PubMed ID: 31173913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential.
    Crooke A; Huete-Toral F; Martínez-Águila A; Colligris B; Pintor J
    Expert Opin Drug Discov; 2012 Oct; 7(10):989-1001. PubMed ID: 22860991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology.
    Cecilia OM; José Alberto CG; José NP; Ernesto Germán CM; Ana Karen LC; Luis Miguel RP; Ricardo Raúl RR; Adolfo Daniel RC
    J Diabetes Res; 2019; 2019():8562408. PubMed ID: 31511825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of age-related macular degeneration and therapeutic opportunities.
    van Lookeren Campagne M; LeCouter J; Yaspan BL; Ye W
    J Pathol; 2014 Jan; 232(2):151-64. PubMed ID: 24105633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. VEGF inhibitors for AMD and diabetic macular edema.
    Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
    [No Abstract]   [Full Text] [Related]  

  • 51. Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy.
    Nath M; Halder N; Velpandian T
    Indian J Ophthalmol; 2017 Mar; 65(3):191-197. PubMed ID: 28440247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic modifications as potential therapeutic targets in age-related macular degeneration and diabetic retinopathy.
    Kwa FA; Thrimawithana TR
    Drug Discov Today; 2014 Sep; 19(9):1387-93. PubMed ID: 24717156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders.
    Giri A; Mehan S; Khan Z; Das Gupta G; Narula AS; Kalfin R
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3867-3895. PubMed ID: 38225412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of macular oedema on the measurement of macular pigment optical density.
    Thiele S; Rauscher FG; Wiedemann P; Dawczynski J
    Graefes Arch Clin Exp Ophthalmol; 2016 Mar; 254(3):455-65. PubMed ID: 26100452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melatonin in Reproductive Medicine: A Promising Therapeutic Target?
    Feng X; Zhang Y; Li N; Zhang Y; Zheng Q; Sun M; Tang J; Xu Z
    Curr Med Chem; 2023; 30(27):3090-3118. PubMed ID: 36200146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease.
    Campbell M; Doyle SL
    Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melatonin: a pleiotropic molecule regulating inflammation.
    Radogna F; Diederich M; Ghibelli L
    Biochem Pharmacol; 2010 Dec; 80(12):1844-52. PubMed ID: 20696138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic stratagems for vascular degenerative disorders of the posterior eye.
    Jain GK; Warsi MH; Nirmal J; Garg V; Pathan SA; Ahmad FJ; Khar RK
    Drug Discov Today; 2012 Jul; 17(13-14):748-59. PubMed ID: 22504325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress.
    Yoo YM; Joo SS
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective Effect of Melatonin against Oxidative Stress-Induced Apoptosis and Enhanced Autophagy in Human Retinal Pigment Epithelium Cells.
    Chang CC; Huang TY; Chen HY; Huang TC; Lin LC; Chang YJ; Hsia SM
    Oxid Med Cell Longev; 2018; 2018():9015765. PubMed ID: 30174783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.